Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$8.64 +0.1%	$8.07	$5.20 ▼ $10.67	$1.17B	1.15	1.36 million shs	4.36 million shs
KRYS Krystal Biotech	$138.88 -2.6%	$140.66	$122.80 ▼ $219.34	$4.12B	0.65	289,301 shs	418,422 shs
RYTM Rhythm Pharmaceuticals	$62.73 +2.1%	$62.45	$39.46 ▼ $69.89	$3.91B	2.3	553,455 shs	857,993 shs
ZLAB Zai Lab	$34.74 -4.0%	$33.46	$16.01 ▼ $44.34	$3.99B	0.96	907,643 shs	759,523 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+0.12%	+11.20%	+8.27%	+4.22%	+56.81%
KRYS Krystal Biotech	-2.60%	+4.85%	+12.58%	-24.49%	-23.77%
RYTM Rhythm Pharmaceuticals	+2.10%	+1.19%	+5.27%	+14.47%	+57.34%
ZLAB Zai Lab	-4.01%	+0.55%	+14.73%	-6.84%	+93.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.73 of 5 stars	3.5	1.0	0.0	2.8	0.8	1.9
KRYS Krystal Biotech	4.5964 of 5 stars	3.5	1.0	4.7	3.1	2.5	1.9
RYTM Rhythm Pharmaceuticals	3.8999 of 5 stars	3.5	2.0	4.3	2.1	0.8	0.6
ZLAB Zai Lab	3.3505 of 5 stars	3.4	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.10% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	52.02% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	23.24% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	36.35% Upside

Current Analyst Ratings Breakdown

Latest AUPH, KRYS, ZLAB, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
4/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$221.00 ➝ $240.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $92.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.31 per share	27.98	$2.68 per share	3.22
KRYS Krystal Biotech	$290.52M	13.82	$4.52 per share	30.75	$32.90 per share	4.22
RYTM Rhythm Pharmaceuticals	$130.13M	30.67	N/A	N/A	$0.35 per share	179.23
ZLAB Zai Lab	$398.99M	9.61	N/A	N/A	$7.68 per share	4.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.86	15.43	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	33.38	13.78	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest AUPH, KRYS, ZLAB, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
KRYS Krystal Biotech	N/A	9.65	9.27
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
KRYS Krystal Biotech	86.29%
RYTM Rhythm Pharmaceuticals	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
KRYS Krystal Biotech	13.70%
RYTM Rhythm Pharmaceuticals	6.10%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
ZLAB Zai Lab	1,869	110.33 million	104.86 million	Optionable

AUPH, KRYS, ZLAB, and RYTM Headlines

Recent News About These Companies

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $96,647.75 in Stock

2 hours ago | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

3 hours ago | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen

June 28 at 2:35 AM | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Downgraded to Hold Rating by Wall Street Zen

June 27 at 12:09 AM | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 2,675 Shares of Stock

June 27 at 5:55 PM | marketbeat.com

Ying Du Sells 23,669 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

June 27 at 5:55 PM | marketbeat.com

Zai Lab Limited (ZLAB) - Yahoo Finance

June 27 at 3:35 PM | finance.yahoo.com

Cantor Fitzgerald Expects Reduced Earnings for Zai Lab

June 26 at 2:21 AM | americanbankingnews.com

Analysts Offer Predictions for Zai Lab FY2025 Earnings

June 25 at 6:12 AM | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director Sells 13,814 Shares of Stock

June 24, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis Sells 13,814 Shares

June 23, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 23, 2025 | marketbeat.com

Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis

June 20, 2025 | msn.com

Zai Lab (NASDAQ:ZLAB) Shares Down 5.4% - Time to Sell?

June 20, 2025 | marketbeat.com

Mission Wealth Management LP Buys Shares of 20,000 Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 18, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why

June 17, 2025 | marketbeat.com

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

June 13, 2025 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Zai Lab FY2026 Earnings

June 11, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sets New 1-Year High - Here's What Happened

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, KRYS, ZLAB, and RYTM Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.62 -0.02 (-0.23%)

As of 06/27/2025 07:57 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Krystal Biotech NASDAQ:KRYS

$138.88 -3.70 (-2.60%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$136.25 -2.63 (-1.89%)

As of 06/27/2025 05:59 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Rhythm Pharmaceuticals NASDAQ:RYTM

$62.73 +1.29 (+2.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$62.81 +0.08 (+0.13%)

As of 06/27/2025 07:50 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Zai Lab NASDAQ:ZLAB

$34.74 -1.45 (-4.01%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$34.73 -0.01 (-0.03%)

As of 06/27/2025 05:12 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time